Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
3.600
+0.200 (5.88%)
At close: May 29, 2025, 4:00 PM
3.570
-0.030 (-0.83%)
After-hours: May 29, 2025, 4:04 PM EDT
Contineum Therapeutics Stock Forecast
CTNM's stock price has decreased by -75.51% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Contineum Therapeutics stock ranges from a low of $16 to a high of $31. The average analyst price target of $22.5 forecasts a 525.00% increase in the stock price over the next year.
Price Target: $22.50 (+525.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $25 → $20 | Buy | Maintains | $25 → $20 | +455.56% | May 19, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +761.11% | May 15, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +538.89% | Mar 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $25 | Buy | Initiates | $25 | +594.44% | Mar 7, 2025 |
| Baird | Baird | Buy Maintains $32 → $16 | Buy | Maintains | $32 → $16 | +344.44% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
5.10M
Revenue Next Year
n/a
from 5.10M
EPS This Year
-2.36
from -2.18
EPS Next Year
-3.02
from -2.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 31.5M | n/a | n/a |
| Avg | 5.1M | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.34 | -2.58 | -2.69 |
| Avg | -2.36 | -3.02 | -2.82 |
| Low | -2.69 | -3.76 | -2.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.